AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23131884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20657852 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric technique
Number of subjects: 40
Study 20657852 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical technique
Number of subjects: 40
Study 18490667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 2747
Study 18490667 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 2747
Study 16018747 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical periodontal therapy
Number of subjects: 14
Study 16018747 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 14
Study 16018747 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 12426517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal methadone (10 mg)
Number of subjects: 8
Study 12426517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methadone (10 mg)
Number of subjects: 8
Study 12426517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methadone (10 mg)
Number of subjects: 8
Study 10557507 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite-level interventions for smoking and health-related outcomes
Number of subjects: 0
Study 10557507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for individual-level characteristics
Number of subjects: 0
Study 8765442 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ondansetron
Number of subjects: 0
Study 8765442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus metoclopramide
Number of subjects: 0
Study 8765442 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ondansetron
Number of subjects: 0
Study 1834161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg loading dose; A: 4 mg i.v. + 4 mg orally; B: 8 mg i.v.), followed by oral treatment for 5 days (A: 6‐hourly; B: 8 mg 8‐hourly)
Number of subjects: 35
Study 6349653 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (200 mg/day for 1 week, 250 mg/day for 2nd week, 300 mg/day for 3rd to 8th week)
Number of subjects: 98
Study 6349653 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (100 mg/day for 1 week, 125 mg/day for 2nd week, 150 mg/day for 3rd to 8th week)
Number of subjects: 98
Study 30773608 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Positive Birth After Caesarean care plus a decision aid booklet
Number of subjects: 297
Study 30773608 — intervention group
Group type: COMPARATOR
Intervention: Standard Positive Birth After Caesarean care
Number of subjects: 297
Study 30158029 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine injection (20 ml) at port sites
Number of subjects: 120
Study 30158029 — intervention group
Group type: COMPARATOR
Intervention: No bupivacaine injection
Number of subjects: 120
Study 26871297 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release guanfacine hydrochloride (GXR)
Number of subjects: 528
Study 26871297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 25024031 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based patient-specific instrumentation
Number of subjects: 90
Study 25024031 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based patient-specific instrumentation
Number of subjects: 90
Study 25024031 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 90
Study 25024031 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based vs CT-based patient-specific instrumentation
Number of subjects: 90
Study 25024031 — intervention group
Group type: COMPARATOR
Intervention: MRI-based and CT-based patient-specific instrumentation vs Conventional instrumentation
Number of subjects: 90
Study 22830389 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 25 mg once weekly
Number of subjects: 60
Study 22830389 — intervention group
Group type: COMPARATOR
Intervention: MTX 10 mg once weekly
Number of subjects: 60
Study 20832994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (bolus injection of 100 μg/kg, continuous injection of 60‐100 μg/kg/h for 5 days)
Number of subjects: 31
Study 20832994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 31
Study 20832994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicorandil)
Number of subjects: 31
Study 17369799 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g day(‐1) of creatine monohydrate for 21 days)
Number of subjects: 16
Study 17369799 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 16
Study 16379507 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (0.5-3.5 mg/day)
Number of subjects: 101
Study 16379507 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101
Study 12462385 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated referral from screening to diagnostic breast imaging
Number of subjects: 1578
Study 12462385 — intervention group
Group type: COMPARATOR
Intervention: Pilot project initiatives
Number of subjects: 1578
Study 12462385 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsied women
Number of subjects: 1578
Study 12462385 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened time to diagnosis
Number of subjects: 1578
Study 10051720 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with HDM extract (Alavac, Bencard) for 2 years
Number of subjects: 26
Study 10051720 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SIT)
Number of subjects: 26
Study 7770614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 2186476 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEPA
Number of subjects: 17
Study 2186476 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 17
Study 658107 — intervention group
Group type: EXPERIMENTAL
Intervention: bendroflumethiazide (bft) 2.5 mg and KCl 1.5 g daily for 2 weeks
Number of subjects: 8
Study 658107 — intervention group
Group type: EXPERIMENTAL
Intervention: bendroflumethiazide (bft) 5 mg and KCl 1.5 g daily for 2 weeks
Number of subjects: 8
Study 658107 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment for 4 weeks
Number of subjects: 8
Study 30563770 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPI)
Number of subjects: 10942
Study 30563770 — intervention group
Group type: COMPARATOR
Intervention: Non-Glycoprotein IIb/IIIa inhibitors (non-GPI)
Number of subjects: 10942
Study 28482901 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily listening to specially composed songs for 12 weeks
Number of subjects: 111
Study 28482901 — intervention group
Group type: COMPARATOR
Intervention: Daily relaxation for 12 weeks
Number of subjects: 111
Study 25218898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol TRAJ group membership (high vs. low cortisol)
Number of subjects: 91
Study 25218898 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cortisol TRAJ group
Number of subjects: 91
Study 25218898 — intervention group
Group type: EXPERIMENTAL
Intervention: High cortisol TRAJ group
Number of subjects: 91
Study 25218898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative inflammatory load score (ILS)
Number of subjects: 91
Study 23023407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% pranoprofen (PN) eye drops, 4 times daily for 4 weeks
Number of subjects: 75
Study 23023407 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluorometholone (FL) eye drops, 4 times daily for 4 weeks
Number of subjects: 75
Study 21613025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin desensitizer and ozone treatment
Number of subjects: 0
Study 21613025 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 19111473 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/(m2 12 h), days 1‐14 plus oxaliplatin 130 mg/m2 day 1, every 3 weeks
Number of subjects: 348
Study 19111473 — intervention group
Group type: COMPARATOR
Intervention: Weekly infusional 5‐FU 2250 mg/m2 over 48 h plus bimonthly oxaliplatin 85 mg/m2
Number of subjects: 348
Study 19111473 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin
Number of subjects: 348
Study 19111473 — intervention group
Group type: COMPARATOR
Intervention: Weekly infusional 5‐FU plus oxaliplatin
Number of subjects: 348
Study 16710073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone (7.5 mg/day)
Number of subjects: 95
Study 16710073 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose pioglitazone (15 mg/day)
Number of subjects: 95
Study 15080850 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (Duphalac)
Number of subjects: 65
Study 15080850 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-4000 (Forlax)
Number of subjects: 65
Study 11876663 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 248
Study 11876663 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment
Number of subjects: 248
Study 11876663 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 248
Study 9846303 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial left lateralization (20 degrees)
Number of subjects: 204
Study 9846303 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 204
Study 7866597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose acetylsalicylic acid (ASA, aspirin) 75 mg daily
Number of subjects: 19196
Study 7866597 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist felodipine 5 mg daily
Number of subjects: 19196
Study 7866597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19196
Study 2770103 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% amino acid dialysis solution
Number of subjects: 6
Study 269880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pluronic F‐127 plus sodium citrate gel
Number of subjects: 176
Study 269880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pluronic F‐127 gel
Number of subjects: 176
Study 269880 — intervention group
Group type: COMPARATOR
Intervention: Strontium chloride dentifrice
Number of subjects: 176
Study 269880 — intervention group
Group type: COMPARATOR
Intervention: 0.4% stannous fluoride gel
Number of subjects: 176
Study 269880 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 176
Study 27820659 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA)
Number of subjects: 15187
Study 27820659 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) alone
Number of subjects: 15187
Study 27820659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15187
Study 26028283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting/exercise/saline infusion
Number of subjects: 23
Study 26028283 — intervention group
Group type: COMPARATOR
Intervention: Fasting/rest/saline (control)
Number of subjects: 23
Study 26028283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting/rest/iv glucose infusions
Number of subjects: 23
Study 26028283 — intervention group
Group type: COMPARATOR
Intervention: Fasting/rest/saline
Number of subjects: 23
Study 24015701 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 10
Study 24015701 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 10
Study 24015701 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo control
Number of subjects: 10
Study 21991787 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS) for 72 hours
Number of subjects: 80
Study 21991787 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 80
Study 19156856 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the ETS reduction trial
Number of subjects: 153
Study 19156856 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in the ETS reduction trial
Number of subjects: 153
Study 19156856 — intervention group
Group type: COMPARATOR
Intervention: Primary caregiver being a smoker
Number of subjects: 153
Study 19156856 — intervention group
Group type: COMPARATOR
Intervention: Primary caregiver being female
Number of subjects: 153
Study 19156856 — intervention group
Group type: COMPARATOR
Intervention: CNS tumor diagnosis
Number of subjects: 153
Study 19156856 — intervention group
Group type: COMPARATOR
Intervention: No history of chemotherapy
Number of subjects: 153
Study 19156856 — intervention group
Group type: COMPARATOR
Intervention: History of surgery prior to study recruitment
Number of subjects: 153
Study 19156856 — intervention group
Group type: COMPARATOR
Intervention: Future radiation therapy planned post study recruitment
Number of subjects: 153
Study 16708043 — intervention group
Group type: EXPERIMENTAL
Intervention: Client Adherence Profiling and Intervention Tailoring (CAP-IT)
Number of subjects: 240
Study 16708043 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study 15119910 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), administered 3 times weekly
Number of subjects: 253
Study 11157412 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular menstrual cycles
Number of subjects: 33434
Study 11157412 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular menstrual bleeding duration
Number of subjects: 33434
Study 11157412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both irregular menstrual cycles and irregular menstrual bleeding
Number of subjects: 33434
Study 11157412 — intervention group
Group type: COMPARATOR
Intervention: One menstrual disturbance
Number of subjects: 33434
Study 9022435 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by practice doctors
Number of subjects: 2152
Study 9022435 — intervention group
Group type: COMPARATOR
Intervention: Care provided by deputising doctors
Number of subjects: 2152
Study 30646153 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT plus CT of the abdomen and pelvis
Number of subjects: 171
Study 30646153 — intervention group
Group type: COMPARATOR
Intervention: CT of the abdomen and pelvis
Number of subjects: 171
Study 27302143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate plus sodium hyaluronate (9 mg)
Number of subjects: 80
Study 27302143 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate plus saline solution
Number of subjects: 80
Study 25609319 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (CHO)
Number of subjects: 120
Study 23560256 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem with polyacrylic acid pretreatment (RLXU-P)
Number of subjects: 56
Study 23560256 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite with polyacrylic acid pretreatment (MCE-P)
Number of subjects: 56
Study 23560256 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RLXU)
Number of subjects: 56
Study 23560256 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite (MCE)
Number of subjects: 56
Study 23560256 — intervention group
Group type: COMPARATOR
Intervention: RelyX ARC (ARC)
Number of subjects: 56
Study 23560256 — intervention group
Group type: EXPERIMENTAL
Intervention: SeT (ST)
Number of subjects: 56
Study 19036898 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily)
Number of subjects: 14
Study 19036898 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS inhibition (10 mM N(G)-nitro-l-arginine methyl ester)
Number of subjects: 14
Study 19036898 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 14
Study 17382603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg 3 times daily for 3 days
Number of subjects: 310
Study 17382603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin-loperamide combination therapy
Number of subjects: 310
Study 17382603 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (4 mg initially followed by 2 mg after each unformed stool)
Number of subjects: 310
Study 17382603 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 310
Study 17382603 — intervention group
Group type: COMPARATOR
Intervention: Loperamide alone
Number of subjects: 310
Study 14711550 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (50 microg/d of E(2) and 140-170 microg/d of norethisterone acetate; n = 12)
Number of subjects: 24
Study 14711550 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (2 mg of E(2) and 1 mg of norethisterone acetate; n = 12)
Number of subjects: 24
Study 11290880 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (DPZ) 5-10 mg/d
Number of subjects: 60
Study 11290880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (Riv) 1.5 to 12 mg/d
Number of subjects: 60
Study 11290880 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 2,000 IU/d
Number of subjects: 60
Study 9868823 — intervention group
Group type: EXPERIMENTAL
Intervention: Education in psychiatric nursing
Number of subjects: 0
Study 8049645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic therapy
Number of subjects: 0
Study 8049645 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis
Number of subjects: 0
Study 8049645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 8049645 — intervention group
Group type: EXPERIMENTAL
Intervention: New growth factors
Number of subjects: 0
Study 2465391 — intervention group
Group type: COMPARATOR
Intervention: PVP16B (cisplatin plus etoposide plus bleomycin) administered in three courses over 9 weeks
Number of subjects: 184
Study 2465391 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP16B (cisplatin plus etoposide plus bleomycin) administered in four courses over 12 weeks
Number of subjects: 184
Study 958261 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil plus prednisone
Number of subjects: 21
Study 958261 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 21
Study 30880470 — intervention group
Group type: EXPERIMENTAL
Intervention: Local-only anesthesia
Number of subjects: 31
Study 30880470 — intervention group
Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 31
Study 31218480 — intervention group
Group type: EXPERIMENTAL
Intervention: Training initiative in person-centered care planning
Number of subjects: 7
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic chest strap monitor (Polar H7)
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: TomTom Spark
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Forerunner 235
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Scosche Rhythm+
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Blaze
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling exercise
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical trainer without arm levers
Number of subjects: 50
Study 28709155 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical trainer with arm levers
Number of subjects: 50
Study 26052831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (optimal facilitation)
Number of subjects: 347
Study 26052831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based intervention
Number of subjects: 347
Study 26052831 — intervention group
Group type: COMPARATOR
Intervention: Classes as usual control
Number of subjects: 347
Study 23534025 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite veneers (Estenia)
Number of subjects: 10
Study 23534025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers (IPS Empress Esthetic)
Number of subjects: 10
Study 23534025 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 10
Study 23534025 — intervention group
Group type: COMPARATOR
Intervention: Resin composite laminate veneers
Number of subjects: 10
Study 21639941 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 102
Study 21639941 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 102
Study 19502254 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 19502254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 16857301 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative learning approach
Number of subjects: 97
Study 16857301 — intervention group
Group type: COMPARATOR
Intervention: Low levels of computer anxiety
Number of subjects: 97
Study 15554757 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (titrated from 25 mg/day to a maximum of 600 mg/day)
Number of subjects: 61
Study 15554757 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (during controlled and open-label studies)
Number of subjects: 61
Study 15554757 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (only during the open-label trial)
Number of subjects: 61
Study 15554757 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (not specified dosage)
Number of subjects: 61
Study 15554757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11470302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching the ankle to a fixed dorsiflexion angle for 20 min followed by a 2 min release (subjects either relaxed or performed isometric contractions)
Number of subjects: 8
Study 11470302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching the ankle for 20 min, then releasing between 0 and 20 min, then stretching again (24 subjects)
Number of subjects: 8